How advocacy programmes improve breast cancer care?

Rita SAKR
surgeon, Dubai
CONTINUE READING
What are the predictive tools in breast cancer, how do you classified them?

What are the predictive tools in breast cancer, how do you classified them?

Joseph GLIGOROV
oncologist, Paris, France
CONTINUE READING
What is the significance of HER2 amplification and how does it affect the use of antibody-drug conjugates (ADCs)?

What is the significance of HER2 amplification and how does it affect the use of antibody-drug conjugates (ADCs)?

Joseph GLIGOROV
oncologist, Paris, France
CONTINUE READING
How AI will help us to better define patient populations? What for?

How AI will help us to better define patient populations? What for?

Joseph GLIGOROV
oncologist, Paris, France
CONTINUE READING

What are the options in HER2 postive breast cancer treatments are we moving to t-DXd in first line?

Hassan GHAZAL
oncologist, Dubai
CONTINUE READING

How important are side effects, especially pulmonary toxicity, and how do you manage them?

Hassan GHAZAL
oncologist, Dubai
CONTINUE READING

Where does immunotherapy take place in breast cancer, is there a potential in HER2 positive patients?

Hassan GHAZAL
oncologist, Dubai
CONTINUE READING

Breast cancer dynamics: Molecular signature, Radiotherapy and Nuclear Medicine

At the line-up you’ll find our speakers with exclusives interviews and their full presentation for registered members. Stay tuned, more…
CONTINUE READING

Copyright © 2026 - BCU